## Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics

- 2 in three Kenyan referral hospitals: repeated cross-sectional
- 3 surveys 2020-21
- 4 R. Lucinde<sup>1,\*</sup>, D. Mugo<sup>1</sup>, C. Bottomley<sup>2</sup>, A. Karani<sup>1</sup>, E. Gardiner<sup>1</sup>, R Aziza<sup>3</sup>, J. Gitonga<sup>1</sup>, H. Karania<sup>1</sup>,
- 5 J. Nyagwange<sup>1</sup>, J. Tuju<sup>1</sup>, P. Wanjiku<sup>1</sup>, E. Nzomo<sup>4</sup>, E. Kamuri<sup>5</sup>, K. Thuranira<sup>5</sup>, S. Agunda<sup>5</sup>, G. Nyutu<sup>1</sup>,
- 6 A. Etyang<sup>1</sup>, I. M. O. Adetifa<sup>1,2</sup>, E. Kagucia<sup>1</sup>, S. Uyoga<sup>1</sup>, M. Otiende<sup>1</sup>, E. Otieno<sup>1</sup>, L. Ndwiga<sup>1</sup>, C. N.
- 7 Agoti<sup>1</sup>, R. A. Aman<sup>6</sup>, M. Mwangangi<sup>6</sup>, P. Amoth<sup>6</sup>, K. Kasera<sup>6</sup>, A. Nyaguara<sup>1</sup>, W. Ng'ang'a<sup>7</sup>, L. B.
- 8 Ochola<sup>9</sup>, E. Namdala<sup>10</sup>, O Gaunya<sup>10</sup>, R Okuku<sup>10</sup>, E. Barasa<sup>1,8</sup>, P. Bejon<sup>1,8</sup>, B. Tsofa<sup>1</sup>, L. I. Ochola-
- 9 Oyier<sup>1</sup>, G. M. Warimwe<sup>1,8+</sup>, A. Agweyu<sup>1+</sup>, J. A. G. Scott<sup>1,2,8+</sup>, K. E. Gallagher<sup>1,2+</sup>.
- <sup>\*</sup> Corresponding author: Ruth Lucinde, Epidemiology & Demography Department, KEMRI-
- Wellcome Trust Research Programme CGMR-C, PO Box 230-80108, Kilifi, Kenya. Email:
- 12 RLucinde@kemri-wellcome.org
- 13 Alternate corresponding author: Katherine Gallagher, Department of Infectious Disease
- 14 Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and
- 15 Tropical Medicine, Keppel Street, London, WC1E 7HT, United Kingdom. Email:
- 16 Katherine.gallagher@lshtm.ac.uk
- 17 <sup>+</sup>Contributed equally
- 18 <sup>1</sup> KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
- <sup>2</sup> Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical
- 20 Medicine, Keppel Street, London, UK.
- <sup>3</sup> School of Life Sciences and the Zeeman Institute for Systems Biology & Infectious Disease
- 22 Epidemiology Research (SBIDER), University of Warwick, Coventry, United Kingdom

23 <sup>4</sup> Kilifi County Hospital, Ministry of Health, Government of Kenya 24 <sup>5</sup> Kenyatta National Hospital, Ministry of Health, Government of Kenya 25 <sup>6</sup> Ministry of Health, Government of Kenya, Nairobi, Kenya. 26 <sup>7</sup> Presidential Policy and Strategy Unit, The Presidency, Government of Kenya, Nairobi, Kenya 27 <sup>8</sup> Nuffield Department of Medicine, Oxford University, Oxford, UK 28 <sup>9</sup> Institute of Primate Research, Nairobi, Kenya 29 <sup>10</sup> Busia Country Teaching & Referral Hospital, Busia, Kenya 30 31 Short title: SARS-CoV-2 seroprevalence at antenatal care clinics in three Kenyan referral 32 hospitals 33 Abstract word count: 250/300

Keywords: SARS-CoV-2, serology, sero-surveillance, ante-natal care

34

35

Article: 2997/5000

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

**Abstract** Introduction The high proportion of SARS-CoV-2 infections that have remained undetected presents a challenge to tracking the progress of the pandemic and estimating the extent of population immunity. Methods We used residual blood samples from women attending antenatal care services at three hospitals in Kenya between August 2020 and October 2021 and a validated IgG ELISA for SARS-Cov-2 spike protein and adjusted the results for assay sensitivity and specificity. We fitted a two-component mixture model as an alternative to the threshold analysis to estimate of the proportion of individuals with past SARS-CoV-2 infection. Results We estimated seroprevalence in 2,981 women; 706 in Nairobi, 567 in Busia and 1,708 in Kilifi. By October 2021, 13% of participants were vaccinated (at least one dose) in Nairobi, 2% in Busia. Adjusted seroprevalence rose in all sites; from 50% (95%CI 42-58) in August 2020, to 85% (95%CI 78-92) in October 2021 in Nairobi; from 31% (95%CI 25-37) in May 2021 to 71% (95%CI 64-77) in October 2021 in Busia; and from 1% (95% CI 0-3) in September 2020 to 63% (95% CI 56-69) in October 2021 in Kilifi. Mixture modelling, suggests adjusted cross-sectional prevalence estimates are underestimates; seroprevalence in October 2021 could be 74% in Busia and 72% in Kilifi. **Conclusions** There has been substantial, unobserved transmission of SARS-CoV-2 in Nairobi, Busia and Kilifi Counties. Due to the length of time since the beginning of the pandemic, repeated cross-sectional surveys are now difficult to interpret without the use of models to account for antibody waning.

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

Introduction Globally, as countries are confronted with new waves of SARS-CoV-2 infections and new variants, WHO recommendations have focused on enhancing population immunity with the available COVID-19 vaccines(1). In Kenya, as with many lower-middle income countries, COVID-19 vaccine supplies have been limited(2). Vaccination started in March 2021 and by 31st October 2021, 3.7 million people had received their first dose (13.5% of the adult population), 1.6 million had received their second dose (6% of the adult population), with some geographic heterogeneity. In Nairobi 34% were partially vaccinated, 18% were fully vaccinated, compared to Busia where 8% were partially vaccinated, 3% fully vaccinated, and Kilifi where 5% were partially vaccinated, 2% fully vaccinated(3). As vaccine coverage and vaccine-induced immunity is still considered to be low in Kenya, it remains important to track the potential protection conferred by natural infection. By the 31st October 2021, Kenya had experienced four waves of infections, and reported a total of 253,310 confirmed cases and 5281 deaths. However, with just 3.9% of the population over 65 years of age(4), the proportion of infections that have been asymptomatic is likely to be very high(5). Additionally, limited access to tests and low uptake of testing makes it likely that a substantial proportion of cases have remained undetected. Measuring the prevalence of antibodies to SARS-CoV-2 is an alternative way to estimate the cumulative incidence of infection. A number of serological assays have been developed and perform well with high sensitivity and specificity(6-9). We have shown that 5.2% of blood donors in Kenya had SARS-CoV-2 antibodies in June 2020 and this had risen to 9.1% in September 2020 and 48.5% by March 2021(10-12). However, it is unclear whether blood donors are representative of the population. In the context of a pandemic, sentinel public health surveillance using residual aliquots of routinely collected blood samples has the potential to overcome participation bias. For example, serosurveillance for HIV among women attending antenatal care was used to track the progress of the

HIV pandemic and showed prevalence estimates that were similar to population samples from the

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

same areas(13, 14). It remains unclear whether pregnancy alters susceptibility to SARS-CoV-2 infection(15); however, a large systematic review has found no difference in risk of becoming symptomatic when comparing pregnant women with confirmed SARS-CoV-2 infection in women of the same age(16, 17). In Kenya, in 2014, 50% of women had had at least one pregnancy or were pregnant by 20 years of age and the coverage of at least one antenatal care visit was 96%(18). Residual blood samples from mothers visiting antenatal care for the first time may therefore represent a relatively unbiased sample of young women, and an alternative sentinel surveillance population to blood donors. Testing an aliquot of blood for antibodies to SARS-CoV-2 is feasible as a venous blood sample (5ml) is already taken to screen mothers for malaria, HIV and syphilis at their first ANC visit. We aimed to determine the prevalence of antibodies against SARS-CoV-2 in mothers attending ANC at three referral hospitals in Kenya. Methods **Setting** In a collaboration between the Kenyan Ministry of Health (MOH) and KEMRI-Wellcome Trust Research Programme (KWTRP), three referral hospitals were engaged. Kenyatta National Hospital (KNH) is the national referral tertiary hospital located in Nairobi, the country's capital city, approximately 3km from the central business district. The population of Nairobi city was 4,397,073 in 2019(4). Busia Country Teaching & Referral Hospital (BCTRH) serves Busia County, an area of 1628 km<sup>2</sup>, with a population of 893,681 (548/km<sup>2</sup>). Kilifi County Hospital (KCH) is the county referral hospital in Kilifi Town. Kilifi county covers an area of 12,000 km<sup>2</sup>, with a predominantly rural population of 1.4 million (116/km<sup>2</sup>)(4).

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

**Study population** All women attending ANC for the first time, who provided a routine blood sample at their clinic visit, were included in the study. Women who did not provide a sample at their first antenatal care visit, or women attending their second or subsequent ANC visit, were excluded. Sample collection and processing In Kenya, a 5ml blood sample is routinely collected at the first ANC visit. After testing for malaria, syphilis and HIV in the hospital laboratory, the residual volume is usually discarded. In this study, all residual samples were set aside and collected daily for SARS-CoV-2 sero-surveillance. Where possible, the following data were collected from hospital records and linked to the residual sample identity number: date of sample, age, sub-county of residence, trimester of pregnancy, presence or absence of COVID19-like symptoms in the last month and COVID-19 vaccination status ascertained via verbal report confirmed via SMS or certificate. No personal identifiers were collected. All samples were tested at the KWTRP laboratories for IgG to SARS-CoV-2 whole spike protein using an adaptation of the Krammer Enzyme Linked Immunosorbent Assay (ELISA)(6). Validation of this assay is described in detail elsewhere (10). Results were expressed as the ratio of test OD to the OD of the plate negative control; samples with OD ratios greater than two were considered positive for SARS-CoV-2 IgG. Sensitivity, estimated in 174 PCR positive Kenyan adults and a panel of 5 sera from the National Institute of Biological Standards in the UK was 92.7% (95% CI 87.9-96.1%); specificity, estimated in 910 serum samples from Kilifi drawn in 2018 was 99.0% (95% CI 98.1-99.5%)(10). **Analysis** We estimated the proportion of samples seropositive for IgG to SARS-CoV-2. Sampling at least 135 women per month from each hospital would provide estimates of seroprevalence in the range 3-25% with a precision of 3-7%. Bayesian modelling was used to adjust seroprevalence estimates for the sensitivity and specificity of the assay. Non-informative priors were used for each parameter

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

(sensitivity, specificity and proportion true positive) and the models were fitted using the RStan software package(19) (see supplementary files for code). Sub-county population densities were extracted from the Kenya National Bureau of Statistics' database(4). To account for the effects of waning IgG in repeated cross-sectional samples, we fitted a twocomponent mixture model to the log<sub>2</sub> OD ratios in unvaccinated individuals. In this model, we assumed that antibody levels follow a normal distribution in previously uninfected individuals and a skew-normal in previously infected individuals. To fit the model, we fixed the standard deviation of the negative component at the value observed in pre-COVID 19 samples. The remaining parameters were estimated using RStan. Details of the priors used in the estimation have been described elsewhere(20). **Patient and Public Involvement** The study was conducted as anonymous public health surveillance at the request of the Kenyan MOH, in response to the COVID-19 pandemic. The study directly addressed the needs of the MOH by providing some information on the extent of the spread of SARS-CoV-2 pandemic within Kenya. The public were not involved in the conceptualisation or implementation of this study. The need for individual informed consent from the women whose samples were studied was waived, the protocol was approved by the Scientific and Ethics Review Unit (SERU) of the Kenya Medical Research Institute (Protocol SSC 4085), the Kenyatta National Hospital – University of Nairobi Ethics Review Committee (Protocol P327/06/2020) and the Busia & Kilifi County health management teams. **Results** Crude and adjusted seroprevalence across time and location In Nairobi, samples were collected in three rounds: round 1, median date 11th August 2020, round 2, median date 22 February 2021, and round 3, median date 30 September 2021. In these time periods,

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

706 women (93%) provided a sample (Supplementary Figure 1). Women were aged between 17 and 45 years (mean 31 years); 275 (40%) attended their first antenatal care visit during their third trimester of pregnancy, although this differed significantly between the rounds: 62% in August 2020, 28% in February 2021 and 35% in September 2021 (p<0.001; Supplementary Table 1). A total of 632 (90%) reported residence in 16 different sub-counties of Nairobi, 267 (42%) of mothers were resident in Embakasi North, East or West sub-counties, and 110 (17%) were resident in Dagoretti North or South sub-counties. The proportion of participants living in high vs. low population density subcounties did not differ by round (supplementary Table 1). Among women who had data on symptoms during the preceding month, 7% reported symptoms in the first two rounds, this significantly differed from the third round where 43% reported symptoms, coinciding with the end of the cold season (June-September). Symptoms were not associated with seropositivity, controlling for age (data not shown). In Nairobi, seroprevalence, adjusted for the sensitivity and specificity of the ELISA, was 50% in August 2020, 32% in February 2021 and 85% in September 2021 (Table 1). In October 2021, 12.7% of women were vaccinated with at least one dose of COVID-19 vaccine, seroprevalence among the unvaccinated was 82%. In Busia, samples were collected in 2 rounds: round 1, median date 3<sup>rd</sup> May, and round 2, median date 5<sup>th</sup> October. In this time period a total of 567 first ANC visits were conducted; 567 (100%) provided a sample (Supplementary Figure 1). Women were aged between 14 and 44 (mean age 27 years). Most women (66%) attended their first ANC in their second trimester, although this differed by round (73%) in May and 60% in October (p=0.007; Supplementary table 1). In May, 40% of women reported symptoms in the last month, which differed significantly from October 2021 where 56% reported symptoms. Symptoms were not associated with seropositivity, controlling for age (data not shown). Adjusted seroprevalence in Busia increased from 31% in May 2021 to 71% in October 2021 (Table 2). Just 6 (2%) of women were vaccinated in October 2021, and seroprevalence remained 71% among the unvaccinated.

Table 1. Seroprevalence of IgG to SARS-CoV-2 among mothers attending antenatal care in Kenyatta National Hospital (KNH), Nairobi

	30 <sup>th</sup> July – 25 <sup>th</sup> August 2020 Adjusted				27 <sup>th</sup> Jan- 11 <sup>th</sup> March 2021 Adjusted				7 <sup>th</sup> September-19 <sup>th</sup> October 2021 Adjusted			
KNH	Seroprevalence		seroprevalence		Seroprevalence		seroprevalence		Seroprevalence		seroprevalence	
Nairobi	n / N	%	%	95% CI	n / N	%	%	95% CI	n / N	%	%	95% CI
All	91 / 196	46.4	49.9	42.1-58.2	80 / 265	30.2	32.1	26.2-38.4	193 / 245	78.8	84.9	78.3-91.5
Age												
17-29 years	39 / 93	41.9	44.9	33.8-56.9	28 / 101	27.7	29.6	20.7-39.2	82 / 101	81.2	87.2	77.9-95.7
30-45 years	44 / 90	48.9	52.5	41.1-63.7	47 / 141	33.3	35.7	27.3-44.3	107 / 139	77.0	83.0	74.0-91.7
Trimester												
First	7 / 17	41.2	44.9	21.2-70.1	27 / 83	32.5	35.0	24.1-46.4	48 / 60	80.0	85.5	73.0-96.1
Second	21 / 53	39.6	42.9	29.8-57.4	34 / 106	32.1	34.5	25.1-44.3	77 / 96	80.2	86.1	76.0-95.5
Third	58 / 114	50.9	54.7	44.6-64.6	18 / 75	24.0	25.8	16.4-37.0	64 / 84	76.2	81.6	71.2-91.7
Any symptoms in	last month*											
Yes	7 / 12	58.3	61.2	33.3-86.1	3 / 18	16.7	20.8	5.5-42.2	80 / 106	75.5	81.2	71.3-90.5
No	78 / 172	45.3	48.7	40.2-57.5	77 / 247	31.2	33.3	26.9-40.0	113 / 139	81.3	87.5	79.3-95.1
Population density	of sub-coun	ty of resid	dence									
$<20000/km^2$	44 / 97	45.4	48.8	38.1-59.4	29 / 104	27.9	29.8	20.6-39.8	86 / 102	84.3	90.6	82.2-97.9
20-81000/km <sup>2</sup>	39 / 79	49.4	53.1	41.0-65.7	40 / 124	32.3	34.6	25.9-44.1	85 / 115	73.9	79.5	70.3-88.5
COVID-19 vaccin	e status†											
Vaccinated	-	-	-	-	-	-	-	-	30 / 31	96.8	96.1	86.2-99.9
Unvaccinated	-	-	-	-	-	-	-	-	163 / 214	76.2	82.1	75.1-89.2

<sup>\*</sup> Women were asked about the full list of COVID-19 symptoms as per the MOH COVID-19 screening form i.e. fever/ chills, general weakness, cough, sore throat, runny nose, shortness of breath, diarrhoea, nausea/ vomiting, headache, irritability/ confusion, pain (muscular/ chest/ abdominal/ joint).

<sup>†</sup> Vaccination status (at least one dose) was not available for the first two rounds of data collection, vaccination began in Kenya in March 2021 and at first targeted specific groups only, we assume that the vaccine coverage among women attended ANC between 27th Jan-11th March was 0%.

Variations in seroprevalence by any of the explanatory variables were not statistically significant in any time period when tested with chi2 test.

Table 2. Seroprevalence of IgG to SARS-CoV-2 among mothers attending antenatal care in Busia County Teaching & Referral Hospital (BCTRH), Busia

	15	<sup>5th</sup> April -	21 May 2	021	20 September – 22 October 2021				
BCTRH, Busia	Seroprevalence		Adjusted seroprevalence		Seroprevalence		Adjusted seroprevalence		
	n / N	<b>%</b>	%	95% CI	n / N	%	%	95% CI	
All	78 / 270	28.9	30.6	24.7-37.1	195 / 297	65.7	70.7	64.1-77.4	
Age									
17-29 years	3 / 14	21.4	26.0	6.5-51.4	128 / 203	63.1	67.8	59.8-76.0	
30-45 years	2/7	28.6	35.3	7.4-71.3	58 / 84	69.0	74.2	62.7-85.4	
Trimester									
First	18 / 51	35.3	38.2	25.1-52.6	50 / 78	64.1	68.7	56.6-80.1	
Second	50 / 192	26.0	27.7	21.3-34.7	114 / 175	65.1	70.1	61.8-78.4	
Third	7 / 22	31.8	35.3	17.3-55.8	26 / 39	66.7	71.2	54.3-86.4	
Any symptoms in last mo	onth*								
Yes	37 / 109	33.9	36.4	26.6-46.2	107 / 164	65.2	70.1	61.6-78.8	
No	41 / 161	25.5	27.0	19.6-35.1	84 / 129	65.1	70.0	60.4-79.3	
COVID-19 vaccination s	tatus <sup>†</sup>								
Vaccinated	-	-	-	-	4 / 6	66.7	67.0	29.8-96.1	
Unvaccinated	-	-	-	-	188 / 288	65.3	70.5	63.8-77.3	

<sup>194</sup> DOB was only available for 22 women in the first round of data collection

<sup>\*</sup> Women were asked about the full list of COVID-19 symptoms as per the MOH COVID-19 screening form i.e. fever/ chills, general weakness, cough, sore throat, runny nose, shortness of breath, diarrhoea, nausea/ vomiting, headache, irritability/ confusion, pain (muscular/ chest/ abdominal/ joint).

<sup>†</sup> Vaccination status (at least one dose) was not available for the first two rounds of data collection, vaccination began in Kenya in March 2021 and at first targeted specific groups only, we assume that the vaccine coverage among women attended ANC between 27th Jan-11th March was 0%.

Variations in seroprevalence by any of the explanatory variables were not statistically significant in any time period when tested with chi2 test.

In Kilifi, 1707 samples were collected between the 18th September 2020 and 22nd October 2021, collection was continuous apart from during the healthcare worker strike (December 2020 to February 2021). No data were available on age, trimester, location, symptoms or COVID-19 vaccination status. Adjusted seroprevalence increased over the period of sample collection from 1% in September 2020 to 63% in October 2021 (p=0.0001, Chi sq test for trend; Table 3).

Table 3: Seroprevalence of IgG to SARS-CoV-2 among mothers attending antenatal care in Kilifi County Hospital (KCH), over time

KCH, Kilifi <sup>1</sup>		Seropre	valence	Adjusted seroprevalence			
		n/N	%	%	95% CI		
Month	Sept-Oct 2020	3 / 265	1.1	0.9	0.0-2.7		
	Nov-Dec 2020	32 / 236	13.6	14.0	9.4-19.5		
	Mar-Apr 2021	55 / 260	21.2	22.2	16.7-28.1		
	May-Jun 2021	104 / 382	27.2	28.9	23.9-34.4		
	Jul-Aug 2021	148 / 260	56.9	61.2	54.4-68.4		
	Sept-Oct 2021	178 / 305	58.4	62.7	56.2-69.1		

No age, trimester or symptom data were available from the ANC records at KCH. Months were combined into 2-month batches due to low numbers

## **Mixture model results**

 $\begin{array}{c} 207 \\ 208 \end{array}$ 

When two distinct distributions were fitted to the data—corresponding to antibody levels in previously infected and previously uninfected individuals—there were substantial overlaps in the distributions, especially at low seroprevalences (Figure 1). As seroprevalence estimates increased, the distributions became more distinct. The mixture model produced estimates of cumulative incidence that were consistently higher than those of the threshold analysis except for the final round in Nairobi, where the results of both analyses were the same (85%) and the distributions hardly overlapped (85%; Figure 2). Median OD ratios among the unvaccinated, seropositive individuals increase over time in all three areas, potentially indicating natural boosting through re-infections (Figure 1, Supplementary Table 2).

Figure 1. Mixture distributions fitted to anti-spike IgG antibody data collected in Kilifi (KCH),

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

Busia and Nairobi (KNH). The red distribution represents predicted responses in individuals previously infected with SARS-CoV-2 and the blue distribution represents predicted responses in previously uninfected individuals. Figure 2. Adjusted and modelled estimates of the cumulative incidence of SARS-CoV-2 **infection.** Estimates are shown with 95% credible intervals. **Discussion** Surveillance for IgG antibodies to SARS-CoV-2 among mothers attending ANC services in three county referral hospitals in Kenya has revealed evidence of a substantial amount of prior infection by October 2021. Seroprevalence is currently highest in Nairobi, then Busia, then Kilifi, correlating with the counties' population densities. In Nairobi, in August 2020, just after the peak of the first wave of SARS-CoV-2 infections, mixture modelling, which attempts to account for the wide range of OD ratios among those exposed to the virus better than the simple threshold analysis(20), indicates a cumulative incidence of 75%, just 4 months after the start of the pandemic. At the same timepoint, 6,727 PCR-confirmed infections had been registered across the city (<1% of the County's population; Supplementary Figure 2). In March 2021, a year after the pandemic began, seroprevalence was lower, 32%. This second group of women reported residing in the same sub-counties and were on average the same age (supplementary table 1). The high levels of transmission of the virus in these locations early in the pandemic may have meant some of these women had been infected at some point in the last year, but had since seroreverted. Data on the rate of seroreversion differs with the assay used(21) and the severity of the initial infection(22); approximately 9-12% with mild symptoms may sero-revert 4-6 months postinfection(23, 24). Additionally, such high seroprevalence earlier in the year may have reduced the number susceptible and dampened transmission within the same communities by March 2021. Modelling indicates the first wave could have predominantly affected communities of low-income

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

earners, more likely to use public hospitals, such as KNH, with the later waves affecting a group including higher-income, private healthcare users(25). In October 2021, seroprevalence in a third group of women was 85%, 76% among those unvaccinated. These women were very similar in age, residence location and trimester to the second group. The survey was conducted just after the fourth wave of cases in Kenya, natural boosting could have occurred in these communities if residents encountered the virus repeatedly(26). This is supported by the higher median OD ratios among unvaccinated, seropositive individuals in the third round compared to both of the previous rounds. The proportion vaccinated with at least one dose (13%) is lower than the average for Nairobi adults at this time of 34%(3), although nationally only 13.5% of the population were vaccinated with one dose at this time point. In Busia, seroprevalence in May 2021 was 31% using the threshold analysis, and 51% using the mixture model analysis. The two distributions of OD ratios had a substantial amount of overlap leading to uncertainty in the estimate from mixture modelling at this time point. Threshold seroprevalence increased to 71% in October 2021. By 21st October 2021 only 2% of our study population were vaccinated with at least one dose, lower than the nationally reported coverage of 8% in Busia(3). Western Kenya was affected in the fourth wave of the pandemic in July-September 2021 and the seroprevalence represents a substantial amount of natural infection. Seroprevalence steadily increased in Kilifi during the sampling timeframe to 63% (using the threshold analysis) or 72% (using the mixture model analysis) in October 2021. The slower increase in seroprevalence in Kilifi compared to Nairobi is consistent with modelling suggesting that the initial wave of the COVID-19 pandemic was concentrated in urban centres, with subsequent spread increasingly affecting rural areas(25); Kilifi County reported a marked increase in the number of infections in December 2020 (Supplementary Figure 2).

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

A strength of this analysis is the use of a rigorously validated serological assay, using locally relevant control populations and reference panels from the National Institute for Biological Standards and Control (NIBSC) in the UK(27). The threshold used to define seropositivity was chosen to prioritise specificity over sensitivity, i.e. to minimize the number of false positives. The very low crude seroprevalence (0/82; 0%) in the first month of samples from Kilifi adds confirmation that the specificity of this assay is very high. Although sero-surveillance among pregnant women has been used as a proxy for population-based SARS-CoV-2 surveillance in high income countries (28-34), the representativeness of the sample in Kenya is unknown. A national survey in 2014 indicated 18% of the population utilised public hospitals at their last visit to outpatient services (a further 40% utilized public health centres or dispensaries). Utilisation of public health services was correlated with lower education levels(35). The seroprevalence estimates from women attending ANC differ from the seroprevalence estimates available from blood donor samples. The Nairobi seroprevalence of 50% in August is substantially higher than the 10% seroprevalence reported among blood donors in the same county in June-August 2020(10), however in March 2021, 32% seroprevalence in ANC was lower than the estimated 62% seroprevalence in blood donors(12). The majority of expectant mothers attending ANC in KNH consistently came from 5 sub-counties close to the hospital, which are densely populated with lowincome earners(4). Blood transfusion donors are likely to be more heterogenous and widely distributed across Nairobi including areas of lower population density and greater affluence. The estimates from ANC in Kilifi in September 2020 (1%) and April 2021 (22%) were lower than the 14.1% seroprevalence reported among blood donors from Coastal Counties in September 2020 and the 43% seroprevalence among blood donors in Jan-March 2021(10-12). Blood donations come from across the county including urban centres such as Malindi, whereas women attending ANC in Kilifi represent a less heterogenous semi-urban group. It is clear that viral transmission has been heterogenous in terms of geography and socioeconomic status, seroprevalence estimates from

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

multiple different sentinel populations provide more reliable indicators of the development of the pandemic than any one estimate alone. The impact of pregnancy on susceptibility to SARS-CoV-2 infection is unclear(15); however, comparisons of infected pregnant women with non-pregnant women of the same age suggests that a similar proportion of infections become symptomatic (16). This would suggest a similar proportion of pregnant and non-pregnant women mount a protective antibody response and seroprevalence estimates are generalisable to non-pregnant women of the same age. In a comparison of samples from blood donors and ANC in Australia, the two sample sets estimated seroprevalence within 0.1% of each other, although overall prevalence was very low(36). Additionally, seroprevalence in blood donors in Kenya did not differ by sex(10), suggesting that these results from pregnant women may be generalisable to men between 17-45 years of age, residing in the same areas. Our analysis is constrained by the nature of the anonymised surveillance data available. Data on age, trimester and location for the women in Kilifi would have allowed more valid comparisons with data from other sources. It is difficult to assess how comparable the different rounds from the same location are, without more data. As discussed, we lack local data on the rate of antibody waning, which is important to estimate cumulative incidence of infection from snapshot seroprevalence estimates (37, 38). This is especially important in populations, like those reported here, where ongoing transmission may cause 'natural boosting' (37, 39, 40). **Conclusions** This seroprevalence study of women attending ANC clinics suggests there has been substantial, unobserved transmission of SARS-CoV-2 within communities in Nairobi, Busia and Kilifi Counties. However, it is becoming difficult to interpret the results of cross-sectional seroprevalence studies due to the length of the pandemic(41). To attempt to account, to some extent, for antibody waning, we have used mixture modelling, this suggests that 85% of the population using a public hospital in

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

Nairobi have been previously infected with SARS-COV-2. At least in the short-term, asymptomatic infection is protective(26) and these seroprevalence estimates should be taken into account when estimating population level immunity. Increases in antibody concentration over time implies an increasing level of population protection that may be attributable to reinfections. **Acknowledgements** We thank the Kenyatta National Hospital, Busia Country Teaching & Referral Hospital and Kilifi County Hospital employees who collected the samples during routine ANC visits and the women themselves for providing samples for routine health screening. We thank Rebeccah Ayako, Evalyne Akinyi and Cedrick Shikoli at the Institute of Primate Research for processing the ANC samples from KNH. We thank F. Krammer for providing the plasmids used to generate the spike protein used in this work. Development of SARS-CoV-2 reagents was partially supported by the NIAID Centres of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C. The COVID-19 convalescent plasma panel (NIBSC 20/118) and research reagent for SARS-CoV-2 Ab (NIBSC 20/130) were obtained from the NIBSC, UK. We also thank the WHO SOLIDARITY II network for sharing of protocols and for facilitating the development and distribution of control reagents. This paper has been published with the permission of the director, Kenya Medical Research Institute. For the purpose of Open Access, the author has applied a CC-BY public copyright licence to any author accepted manuscript version arising from this submission. **Funding** This project was funded by the Wellcome Trust (grants 220991/Z/20/Z and 203077/Z/16/Z), the Bill and Melinda Gates Foundation (INV-017547), and the Foreign Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039) and is part of an integrated

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360361

362

363364

programme of SARS-CoV-2 sero-surveillance in Kenya led by KEMRI Wellcome Trust Research Programme. A.A. is funded by a DFID/MRC/NIHR/Wellcome Trust Joint Global Health Trials Award (MR/R006083/1), J.A.G.S. is funded by a Wellcome Trust Senior Research Fellowship (214320) and the NIHR Health Protection Research Unit in Immunisation, I.M.O.A. is funded by the United Kingdom's Medical Research Council and Department For International Development through an African Research Leader Fellowship (MR/S005293/1) and by the NIHR-MPRU at UCL (grant 2268427 LSHTM). G.M.W. is supported by a fellowship from the Oak Foundation. C.N.A. is funded by the DELTAS Africa Initiative [DEL-15-003], and the Foreign, Commonwealth and Development Office and Wellcome (220985/Z/20/Z). S.U. is funded by DELTAS Africa Initiative [DEL-15-003], L.I.O.-O. is funded by a Wellcome Trust Intermediate Fellowship (107568/Z/15/Z). R.A is funded by National Institute for Health Research (NIHR) (project reference 17/63/82) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the authors and not necessarily those of the funding agencies **Conflict of Interest** All authors: No reported conflicts. **Author contributions** Conceptualisation: A. Agweyu, J. A. G. Scott, G. M. Warimwe, K. E. Gallagher Data curation: G. Nyutu Formal statistical analysis: K Gallagher, Christian Bottomley Funding acquisition: A Agweyu J. A. G. Scott, G. M. Warimwe Investigation (Data collection and Lab): R. Lucinde, D. Mugo, A. Karani, E. Gardiner, J. Gitonga, H. Karanja, J. Nyagwange, J. Tuju, P. Wanjiku, E. Nzomo, E. Kamuri, K. Thuranira, S. Agunda, L. B. Ochola, E. Namdala, O Gaunya, R Okuku

- 365 Methodology: K. Gallagher, C Bottomley
- 366 Project Administration: R Lucinde,
- 367 Supervision: .A Agweyu, J. A. G. Scott, G. M. Warimwe, K. E. Gallagher
- 368 Validation: K Gallagher, G Warimwe
- 369 Vizualisation: K Gallagher, R Aziza, C Bottomley
- 370 Original draft preparation: R Lucinde, K Gallagher
- Review and Editing: R. Lucinde, D. Mugo, C. Bottomley, A. Karani, E. Gardiner, R Aziza, J.
- 372 Gitonga, H. Karanja, J. Nyagwange, J. Tuju, P. Wanjiku, E. Nzomo, E. Kamuri, K. Thuranira, S.
- 373 Agunda, G. Nyutu, A. Etyang, I. M. O. Adetifa, E. Kagucia, S. Uyoga, M. Otiende, E. Otieno, L.
- Ndwiga, C. N. Agoti, R. A. Aman, M. Mwangangi, P. Amoth, K. Kasera, A. Nyaguara, W. Ng'ang'a,
- L. B. Ochola, E. Namdala, O Gaunya, R Okuku, E. Barasa, P. Bejon, B. Tsofa, L. I. Ochola-Oyier, G.
- 376 M. Warimwe, A. Agweyu, J. A. G. Scott, K. E. Gallagher

## References

- 378 1. World Health Organization. COVID-19 vaccines
- 379 <u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines</u> [Accessed 08
- 380 Dec 2021] 2021 [
- World Health Organization. Africa faces 470 million COVID-19 vaccine shortfall in 2021. 16
- 382 September 2021 <a href="https://www.afro.who.int/news/africa-faces-470-million-covid-19-vaccine-shortfall-">https://www.afro.who.int/news/africa-faces-470-million-covid-19-vaccine-shortfall-</a>
- 383 2021 2021 [

- 384 3. Ministry of Health GoK. UPDATES ON COVID-19 VACCINATION EXERCISE 21 October
- 385 2021 https://www.health.go.ke/#1621663315215-d6245403-4901
- 4. Kenya National Bureau of Statistics. Population and Housing Census (<u>www.knbs.or.ke</u>). 2019.
- 5. Seedat S, Chemaitelly H, Ayoub H, Makhoul M, Mumtaz GR, Kanaani ZA, et al. SARS-CoV-2
- infection hospitalization, severity, criticality, and fatality rates. medRxiv. 2020:2020.11.29.20240416.
- Amanat F, Nguyen T, Chromikova V, Strohmeier S, Stadlbauer D, Javier A, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv. 2020:2020.03.17.20037713.
- 391 7. Lassaunière R, Frische A, Harboe ZB, Nielsen AC, Fomsgaard A, Krogfelt KA, et al.
- Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv. 2020:2020.04.09.20056325.
- Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN, et al. Test performance
- evaluation of SARS-CoV-2 serological assays. medRxiv. 2020:2020.04.25.20074856.
- 395 9. Caini S, Bellerba F, Corso F, Diaz-Basabe A, Natoli G, Paget J, et al. Meta-analysis of
- 396 diagnostic performance of serological tests for SARS-CoV-2 antibodies and public health
- 397 implications. medRxiv. 2020:2020.05.03.20084160.
- 398 10. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of
- anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science (New York, NY).
- 400 2020:eabe1916.
- 401 11. Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, et al. Temporal trends
- of SARS-CoV-2 seroprevalence in transfusion blood donors during the first wave of the COVID-19
- 403 epidemic in Kenya. medRxiv. 2021;2021.02.09.21251404.
- 404 12. Uyoga S, Adetifa IMO, Otiende M, Yegon C, Agweyu A, Warimwe GM, et al. Prevalence of
- SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021. Jama. 2021;326(14):1436-8.
- 407 13. Montana LS, Mishra V, Hong R. Comparison of HIV prevalence estimates from antenatal care
- 408 surveillance and population-based surveys in sub-Saharan Africa. Sexually Transmitted Infections.
- 409 2008;84(Suppl 1):i78-i84.
- 410 14. Kigadye RM, Klokke A, Nicoll A, Nyamuryekung'e KM, Borgdorff M, Barongo L, et al.
- 411 Sentinel surveillance for HIV-1 among pregnant women in a developing country: 3 years' experience
- and comparison with a population serosurvey. AIDS (London, England). 1993;7(6):849-55.
- 413 15. Wastnedge EAN, Reynolds RM, van Boeckel SR, Stock SJ, Denison FC, Maybin JA, et al.
- 414 Pregnancy and COVID-19. Physiol Rev. 2021;101(1):303-18.
- 415 16. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations,
- 416 risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living
- 417 systematic review and meta-analysis. BMJ. 2020;370:m3320.
- 418 17. Hill J, Patrick HS, Ananth CV, O'Brien D, Spernal S, Horgan R, et al. Obstetrical outcomes and
- follow-up for patients with asymptomatic COVID-19 at delivery: a multicenter prospective cohort
- 420 study. Am J Obstet Gynecol MFM. 2021;3(6):100454.
- 421 18. Kenya National Bureau of S, Ministry of HK, National ACCK, Kenya Medical Research I,
- 422 National Council for P, Development/Kenya. Kenya Demographic and Health Survey 2014.
- 423 Rockville, MD, USA; 2015.
- 424 19. Stan Development Team. RStan: the R interface to Stan. R package version 2.21. 2, http://mc-
- 425 <u>stan.org/</u>. 2020 [
- 426 20. Bottomley C, Otiende M, Uyoga S, Gallagher K, Kagucia EW, Etyang AO, et al. Quantifying
- 427 previous SARS-CoV-2 infection through mixture modelling of antibody levels. Nature
- 428 Communications. 2021;12(1):6196.

- 429 21. Eyre DW, Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. Stringent
- 430 thresholds for SARS-CoV-2 IgG assays result in under-detection of cases reporting loss of taste/smell.
- 431 medRxiv. 2020:2020.07.21.20159038.
- 432 22. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid
- 433 Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. New England Journal of
- 434 Medicine. 2020;383(11):1085-7.
- 435 23. Duysburgh E, Mortgat L, Barbezange C, Dierick K, Fischer N, Heyndrickx L, et al. Persistence
- of IgG response to SARS-CoV-2. The Lancet Infectious Diseases. 2021;21(2):163-4.
- 437 24. UK Biobank. UK Biobank Serology Study (report at
- https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb\_serologystudy\_report\_revised\_6months\_jan21.pdf
- 439 ). 2021.
- 440 25. Ojal J, Brand SP, Were V, Okiro EA, Kombe IK, Mburu C, et al. Revealing the extent of the
- 441 COVID-19 pandemic in Kenya based on serological and PCR-test data. medRxiv.
- 442 2020:2020.09.02.20186817.
- 443 26. Boyton RJ, Altmann DM. The immunology of asymptomatic SARS-CoV-2 infection: what are
- the key questions? Nat Rev Immunol. 2021;21(12):762-8.
- 445 27. Giada Mattiuzzo, Emma M. Bentley, Mark Hassall, Stephanie Routley, Samuel Richardson,
- Valentina Bernasconi, et al. Expert Committee on Biological Standardisation: Establishment of the
- WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody; Geneva 9-10
- 448 December 2020. 2020.
- 28. Crovetto F, Crispi F, Llurba E, Figueras F, Gomez-Roig MD, Gratacos E. Seroprevalence and
- clinical spectrum of SARS-CoV-2 infection in the first versus third trimester of pregnancy. medRxiv.
- 451 2020:2020.06.17.20134098.
- 452 29. Mattern J, Vauloup-Fellous C, Zakaria H, Benachi A, Carrara J, Letourneau A, et al. Post
- lockdown COVID-19 seroprevalence and circulation at the time of delivery, France. PLoS One.
- 454 2020;15(10):e0240782.
- 455 30. Flannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, et al.
- 456 SARS-CoV-2 seroprevalence among parturient women in Philadelphia. Science immunology.
- 457 2020;5(49).
- 458 31. Cosma S, Borella F, Carosso A, Sciarrone A, Cusato J, Corcione S, et al. The "scar" of a
- 459 pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy. Journal of
- 460 medical virology. 2020.
- 461 32. Villalaín C, Herraiz I, Luczkowiak J, Pérez-Rivilla A, Folgueira MD, Mejía I, et al.
- Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and
- 463 perinatal outcome. PLoS One. 2020;15(11):e0243029.
- Lumley SF, Eyre DW, McNaughton AL, Howarth A, Hoosdally S, Hatch SB, et al. SARS-
- 465 CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom,
- 466 14 April to 15 June 2020. Eurosurveillance. 2020;25(42).
- 467 34. Haizler-Cohen L, Davidov A, Blitz MJ, Fruhman G. Severe acute respiratory syndrome
- 468 coronavirus 2 antibodies in pregnant women admitted to labor and delivery units. American journal of
- obstetrics and gynecology. 2020.
- 470 35. Ministry of Health GoK. 2013 KENYA HOUSEHOLD HEALTH EXPENDITURE AND
- 471 UTILISATION SURVEY. Nairobi; 2014.
- 472 36. Gidding HF, Machalek DA, Hendry AJ, Quinn HE, Vette K, Beard FH, et al. Seroprevalence of
- 473 SARS-CoV-2-specific antibodies in Sydney, Australia following the first epidemic wave in 2020.
- 474 Med J Aust 2020; https://www.mja.com.au/journal/2020/seroprevalence-sars-cov-2-specific-
- 475 <u>antibodies-sydney-australia-following-first</u> [Preprint, 2 November 2020]. 2020.
- 476 37. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A
- 477 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection,
- and association with severity. Nature Communications. 2020;11(1):4704.
- 479 38. Buss LF, Prete CA, Jr., Abrahim CMM, Mendrone A, Jr., Salomon T, de Almeida-Neto C, et
- 480 al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated
- 481 epidemic. Science (New York, NY). 2021;371(6526):288-92.

- 482 39. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-
- specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature.
- 484 2020;584(7821):457-62.

- 485 40. Otieno G, Murunga N, Agoti C, Gallagher K, Awori J, Nokes D. Surveillance of endemic
- human coronaviruses (HCoV-NL63, OC43 and 229E) associated with childhood pneumonia in Kilifi,
- 487 Kenya [version 2; peer review: 2 approved]. Wellcome Open Research. 2020;5(150).
- 488 41. Bottomley C, Otiende M, Uyoga S, Gallagher K, Kagucia EW, Etyang AO, et al. Improving
- 489 SARS-CoV-2 cumulative incidence estimation through mixture modelling of antibody levels.
- 490 medRxiv. 2021:2021.04.09.21254250.




Figure 1




Figure 2